|
Alglucerase
resources
|
|
|
|
|
|
DRUG INFO
Alglucerase
Drug Name:
Alglucerase
Indication: For treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Pharmacology: Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of alglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside
Mechanism Of Action: Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
Drug Category: Enzyme replacement
Brand Names/Synonyms: Glucosylceramidase precursor;Beta-glucocerebrosidase;Acid beta-glucosidase;D-glucosyl-N-acylsphingosine glucohydrolase;Alglucerase;Imiglucerase; Ceredase (Genzyme Corp)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human Beta-glucocerbrosidase
Chemical Formula: C2532H3854N672O711S16
Half Life: 3.6-10.4 min
Drug Type: Approved Drug
# Accession No: BIOD00037
CAS Registry Number: 37228-64-1; 143003-46-7
|
|
|
|
|
|
Alglucerase News
(When available)
BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
PR Newswire (press release), ...responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products, including Cerezyme and Ceredase. ...
|
|
|
